LH · Labcorp Holdings Inc. · Executive Compensation
$303.40
-1.21 (-0.40%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$25.11B
Shares
81.10M
Volume · Oct 2
56.27K
Avg daily vol (3M)
728.78K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Adam Schechter | President and Chief Executive Officer | $14,927,297 |
| Glenn Eisenberg | Executive Vice President and Chief Financial Officer | $8,682,493 |
| PAUL R. KIRCHGRABER | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $3,016,933 |
| BRIAN J | CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer | $3,008,467 |
| MARK S. SCHROEDER | Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain | $2,843,055 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Adam Schechter | President and Chief Executive Officer | $20,551,605 |
| Glenn Eisenberg | Executive Vice President and Chief Financial Officer | $6,458,708 |
| PAUL R. KIRCHGRABER | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $4,421,426 |
| MARK S. SCHROEDER | Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain | $3,990,629 |
| BRIAN J | CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer | $3,970,629 |
| BRIAN J. CAVENEY | Executive Vice President, Diagnostics Chief Medical Officer | $3,970,629 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Adam Schechter | President and Chief Executive Officer | $14,735,561 |
| Glenn Eisenberg | Executive Vice President and Chief Financial Officer | $4,710,361 |
| MARK S. SCHROEDER | Executive Vice President, and President, Diagnostics, Laboratory Operations and Global Supply Chain | $2,992,580 |
| PAUL R. KIRCHGRABER | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $2,973,651 |
| BRIAN J. CAVENEY | Executive Vice President, Diagnostics Chief Medical Officer | $2,941,132 |
| BRIAN J | CAVENEY Executive Vice President, President, Diagnostics and Chief Medical Officer | $2,941,132 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| DAVID P. KING | Former Chief Executive Officer | $12,933,590 |
| Glenn Eisenberg | Executive Vice President Chief Financial Officer | $8,822,761 |
| Adam Schechter | Chief Executive Officer | $4,617,739 |
| JOHN D. RATLIFF | Former Executive Vice President, Chief Executive Officer of Covance Drug Development | $4,569,469 |
| BRIAN J. CAVENEY | Executive Vice President, Diagnostics Chief Medical Officer | $3,449,660 |
| LANCE V. BERBERIAN | Executive Vice President Chief Information and Technology Officer | $2,703,124 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| DAVID P. KING | Former Chief Executive Officer | $12,264,236 |
| JOHN D. RATLIFF | Former Executive Vice President, Chief Executive Officer of Covance Drug Development | $7,489,637 |
| Glenn Eisenberg | Executive Vice President Chief Financial Officer | $3,430,739 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| DAVID P. KING | Former Chief Executive Officer | $11,646,254 |
| JOHN D. RATLIFF | Former Executive Vice President, Chief Executive Officer of Covance Drug Development | $4,997,516 |
| Glenn Eisenberg | Executive Vice President Chief Financial Officer | $3,407,745 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brian J. Caveney, M.D. | Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer | Appointed | 2026-08-14 |
| Megan D. Bailey | Executive Vice President and President, Central Laboratories and International | Resigned | 2026-08-14 |
| John H. Sampson, M.D., Ph.D. | member of the Board | Appointed | 2026-02-09 |
| Mark Schroeder | Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer | Retired | 2025-12-15 |
| Dr. D. Gary Gilliland | Board of Directors | Retired | 2025-12-10 |
| Victor Bulto | member of the Board | Appointed | 2025-11-24 |
| Julia Wang | Executive Vice President and Chief Financial Officer | Appointed | 2024-11-19 |
| Paul Kirchgraber | Senior Advisor to the CEO, and former EVP and CEO of Labcorp's Drug Development business segment | Resigned | 2023-09-11 |
| Paul B. Rothman | member of the Board | Appointed | 2023-06-07 |
| Brian J. Caveney | Executive Vice President, President Early Development & Chief Medical and Scientific Officer | Appointed | 2023-05-04 |
| Mark S. Schroeder | Executive Vice President, President Diagnostics & Chief Operations Officer | Appointed | 2023-05-04 |
| Thomas (Tom) Pike | chief executive officer and chairman of the Board of Directors of the spun-off company | Appointed | 2023-01-05 |
| Thomas (Tom) Pike | president and chief executive officer of its Drug Development Clinical Development business unit | Appointed | 2023-01-05 |
| Kirsten M. Kliphouse | member of the Board | Appointed | 2022-10-13 |
Key facts
CIK
920148
CUSIP
504922105
13F (30d)
33 filings
20 filers
Visit website
Investor relations